Target intelligence / Profile preview

NADPH oxidase isoform (NOX)

Target
NOX
Molecular classification
Enzyme (specifically, ROS-generating enzyme), Transmembrane protein (membrane-bound)
01

Overview

NADPH oxidase isoforms are a family of membrane-bound enzymes whose main function is to catalyze the production of reactive oxygen species by transferring electrons from NADPH to molecular oxygen. Seven isoforms are present in humans: NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1, and DUOX2. Each isoform differs in activation mechanisms, subunit composition, tissue distribution, and regulatory properties, but all share a core domain structure involving electron transport across cellular membranes. These enzymes critically regulate oxidative stress, immune defense, cellular signaling, and can mediate both protective and pathological roles, particularly in inflammation, cardiovascular, neurodegenerative diseases, cancer, and fibrotic disorders. Several drugs have been developed to target specific NOX isoforms due to their involvement in human disease, but isoform selectivity and preservation of essential ROS-mediated signaling remain major therapeutic challenges.

Other names
NADPH oxidaseNOX (with isoform prefixes, e.g. NOX2, NOX4)respiratory burst oxidase homolog (RBOH, mainly in plant biology)
02

Mechanism of action

Direct inhibition of electron transport activity: blocking FAD or heme domains to prevent ROS formation; Blocking subunit assembly (for those isoforms requiring cytosolic subunit interactions, e.g. NOX2); Calcium-dependent inhibitor action (for NOX5 and DUOX1/2)

03

Biological functions

Reactive oxygen species generationCell signaling and redox regulationImmune response (especially in phagocytic cells)Cell proliferationApoptosis
04

Disease associations

Cancer (carcinogenesis, tumor growth)Inflammation (chronic and acute)Cardiovascular disease (e.g. hypertension, atherosclerosis)Neurodegenerative disease (e.g. Alzheimer's, amyotrophic lateral sclerosis)Infection (role in pathogen clearance, but also tissue damage)Fibrosis (e.g. idiopathic pulmonary fibrosis)
05

Safety considerations

Isoform selectivity: many inhibitors affect other FAD-containing enzymes and may cause off-target effectsImmune suppression: broad inhibition of NOX may impair host defense against pathogensEffects on normal cell signaling: since ROS are essential for normal signaling and cell viability
06

Interacting drugs

APX-115 (Ewha-18278): a pan-NOX inhibitor (NOX1, NOX2, NOX4, NOX5)

2 more in the full profile.

07

Biomarkers

ROS levels (superoxide, hydrogen peroxide)NOX2/NOX4 expression (in tissue or blood)Oxidative damage markers (e.g. oxidized proteins/lipids)

Beyond the preview

Go deeper on NADPH oxidase isoform (NOX).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADPH oxidase isoform (NOX).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call